Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...
Infinity Natural Resources IPO raises $265m, bringing company valuation to $1.18bn
The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth ...